论文部分内容阅读
对77例原发性肝癌同步检测血清GGTⅡ、AFP、ALP Ⅰ和AAT,并与肿瘤大小作相关性研究。发现四种生化标记中,GGTⅡ阳性率(87%)最高,即使在AFP<400ng/dl 的病例,其阳性率也可达77.1%。GGTⅡ阳性率与瘤体积呈正相关,既使在14例“小肝癌”中,GGTⅡ阳性率(78.6%)仍高于其他三种标记。随访肝癌病程中GGTⅡ和AFP 动态变化,发现两者可同步或先后异常,也可各自单独阳性。与AFP 一样,GGTⅡ可在B 超或CT 显示异常前出现阳性,表明其具有早期诊断价值。
Serum GGTII, AFP, ALP I and AAT were simultaneously detected in 77 patients with primary liver cancer, and their correlation with tumor size was studied. Among the four biochemical markers, the positive rate of GGTII (87%) was highest. Even in cases with AFP <400ng/dl, the positive rate was 77.1%. The positive rate of GGTII was positively correlated with tumor volume. Even in 14 cases of “small hepatocellular carcinoma”, the positive rate of GGTII (78.6%) was still higher than the other three markers. The dynamic changes of GGTII and AFP in the course of follow-up of liver cancer were found to be synchronous or abnormal in succession, and they could be positive separately. Like AFP, GGTII can be positive before B- or CT abnormalities, indicating its early diagnostic value.